NZ602255A - Method for producing soluble recombinant interferon protein without denaturing - Google Patents

Method for producing soluble recombinant interferon protein without denaturing

Info

Publication number
NZ602255A
NZ602255A NZ602255A NZ60225511A NZ602255A NZ 602255 A NZ602255 A NZ 602255A NZ 602255 A NZ602255 A NZ 602255A NZ 60225511 A NZ60225511 A NZ 60225511A NZ 602255 A NZ602255 A NZ 602255A
Authority
NZ
New Zealand
Prior art keywords
denaturing
recombinant interferon
soluble recombinant
interferon protein
producing soluble
Prior art date
Application number
NZ602255A
Other languages
English (en)
Inventor
Jeffrey Allen
Ping-Hua Feng
Anant Patkar
Keith L Haney
Lawrence Chew
Lei Lei Phokham Sengchanthalangsy
Original Assignee
Pfenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfenex Inc filed Critical Pfenex Inc
Publication of NZ602255A publication Critical patent/NZ602255A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ602255A 2010-03-04 2011-03-02 Method for producing soluble recombinant interferon protein without denaturing NZ602255A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31067110P 2010-03-04 2010-03-04
PCT/US2011/026921 WO2011109556A2 (en) 2010-03-04 2011-03-02 Method for producing soluble recombinant interferon protein without denaturing

Publications (1)

Publication Number Publication Date
NZ602255A true NZ602255A (en) 2014-04-30

Family

ID=44531690

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ602255A NZ602255A (en) 2010-03-04 2011-03-02 Method for producing soluble recombinant interferon protein without denaturing

Country Status (16)

Country Link
US (2) US9187543B2 (https=)
EP (1) EP2542574B1 (https=)
JP (1) JP5840148B2 (https=)
KR (1) KR101857825B1 (https=)
CN (1) CN102906108B (https=)
AU (1) AU2011223627B2 (https=)
BR (1) BR112012022292A2 (https=)
CA (1) CA2791361C (https=)
CL (1) CL2012002378A1 (https=)
CO (1) CO6592086A2 (https=)
ES (1) ES2639398T3 (https=)
MX (1) MX2012010148A (https=)
NZ (1) NZ602255A (https=)
PE (1) PE20130557A1 (https=)
RU (1) RU2573909C2 (https=)
WO (1) WO2011109556A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN104151420A (zh) * 2013-05-15 2014-11-19 复旦大学 长效干扰素及其制备方法和用途
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CN107099569B (zh) * 2017-06-30 2021-05-07 北京生物制品研究所有限责任公司 一种规模化发酵生产重组人干扰素β1b蛋白的方法
AU2021286574A1 (en) * 2020-06-09 2023-01-19 Icosavax, Inc. Method of making virus-like particle
CN116120424A (zh) * 2022-06-06 2023-05-16 江苏靶标生物医药研究所有限公司 一种干扰素α2b可溶性重组表达和分离纯化方法及其应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US5702699A (en) 1982-09-23 1997-12-30 Cetus Corporation Process for the recovery of lipophilic proteins
US4462940A (en) 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US5643566A (en) 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4695455A (en) 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4695462A (en) 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
GB8517071D0 (en) 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
DK174044B1 (da) 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
JP2618618B2 (ja) 1988-03-04 1997-06-11 協和醗酵工業株式会社 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5128130A (en) 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
US5055294A (en) 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5169760A (en) 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
CA2069746A1 (en) 1990-09-28 1992-03-29 Jonathan I. Rosen Hybrid growth factors
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5240834A (en) * 1991-01-22 1993-08-31 Albert Einstein College Of Medicine Of Yeshiva University Solubilization of protein after bacterial expression using sarkosyl
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6171824B1 (en) 1991-08-30 2001-01-09 Fred Hutchinson Cancer Research Center Hybrid cytokines
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
ITFI940106A1 (it) 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
RU2098124C1 (ru) * 1994-10-24 1997-12-10 Общество с ограниченной ответственностью "Ниготек" Способ получения интерферона
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-β (IFN-β) in E. coli
IT1285405B1 (it) 1995-06-06 1998-06-03 Alza Corp Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto.
DE69815707T2 (de) 1997-11-20 2004-07-01 Vical, Inc., San Diego Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür
AU751823B2 (en) 1998-05-14 2002-08-29 Merck Patent Gmbh Fused protein
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
NZ513549A (en) 1999-02-18 2003-03-28 Rmf Dictagene S Malaria vaccine
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
KR100358948B1 (ko) 2000-03-31 2002-10-31 한국과학기술원 인체 과립성 백혈구의 콜로니 자극인자를 분비하는 대장균
JP4799803B2 (ja) 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
AU3070702A (en) 2000-11-07 2002-05-21 Chiron Corp Stabilized inteferon compositions
WO2002077034A2 (en) 2001-02-06 2002-10-03 Merk Patent Gmbh Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
US7189830B2 (en) 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
MXPA03007316A (es) 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
PL371781A1 (en) 2001-07-11 2005-06-27 Maxygen Holdings, Ltd. G-csf conjugates
US20030054435A1 (en) 2001-09-10 2003-03-20 Grabski Anthony C. Method for recovering and analyzing a cellular component of cultured cells without having to harvest the cells first
US20040247562A1 (en) 2001-09-28 2004-12-09 Sang Yup Lee Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
SI21273A (sl) 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
KR100521309B1 (ko) 2002-08-31 2005-10-14 씨제이 주식회사 당쇄화된 인간 과립구 형성인자
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8399217B2 (en) 2003-03-14 2013-03-19 Brookhaven Science Associates, Llc High density growth of T7 expression strains with auto-induction option
CA2545610C (en) 2003-11-19 2014-03-25 Dow Global Technolgies Inc. Auxotrophic pseudomonas fluorescens bacteria for recombinant protein expression
AU2004317306B2 (en) 2003-11-21 2010-09-02 Pelican Technology Holdings, Inc. Improved expression systems with Sec-system secretion
KR100524872B1 (ko) * 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법
ES2663594T3 (es) 2004-01-16 2018-04-16 Pfenex Inc Expresión de proteínas de mamífero en Pseudomonas fluorescens
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
US7923220B2 (en) 2004-12-20 2011-04-12 Cadila Healthcare Limited Process for preparing high levels of interferon beta
US7790174B2 (en) 2004-12-23 2010-09-07 Merck Serono Sa G-CSF polypeptides and uses thereof
GB0605684D0 (en) 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
EP2021489A2 (en) 2006-05-30 2009-02-11 Dow Global Technologies Inc. Codon optimization method
EP1939212A1 (en) 2006-12-20 2008-07-02 LEK Pharmaceuticals D.D. Organic compounds
JP5714230B2 (ja) 2007-01-31 2015-05-07 フェネックス インコーポレイテッド 発現上昇のための細菌リーダー配列
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
JP5444553B2 (ja) 2007-04-27 2014-03-19 フェネックス インコーポレイテッド 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
LT3660032T (lt) 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
NZ603033A (en) 2010-04-01 2014-06-27 Pfenex Inc Methods for g-csf production in a pseudomonas host cell

Also Published As

Publication number Publication date
AU2011223627B2 (en) 2015-06-18
RU2573909C2 (ru) 2016-01-27
PE20130557A1 (es) 2013-05-19
JP5840148B2 (ja) 2016-01-06
EP2542574A2 (en) 2013-01-09
ES2639398T3 (es) 2017-10-26
US20160032345A1 (en) 2016-02-04
CN102906108A (zh) 2013-01-30
US9611499B2 (en) 2017-04-04
EP2542574A4 (en) 2014-01-29
CN102906108B (zh) 2016-01-20
CA2791361A1 (en) 2011-09-09
JP2013524775A (ja) 2013-06-20
AU2011223627A1 (en) 2012-09-27
US20110217784A1 (en) 2011-09-08
CL2012002378A1 (es) 2014-01-10
KR101857825B1 (ko) 2018-05-14
WO2011109556A3 (en) 2012-01-12
CA2791361C (en) 2018-06-12
MX2012010148A (es) 2013-01-22
KR20130018743A (ko) 2013-02-25
EP2542574B1 (en) 2017-08-09
US9187543B2 (en) 2015-11-17
CO6592086A2 (es) 2013-01-02
BR112012022292A2 (pt) 2017-01-10
RU2012141653A (ru) 2014-04-10
WO2011109556A2 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
NZ602255A (en) Method for producing soluble recombinant interferon protein without denaturing
HK1246317A1 (zh) 免疫调节融合蛋白及其用途
WO2014201015A3 (en) Methods and compositions for target dna modification
AR117738A2 (es) Neurotoxinas recombinantes de clostridium botulinum
MX364988B (es) Composición de alimento animal que comprende variantes de fitasa de buttiauxella sp.
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
MY162821A (en) Method of preparing highly dispersible whole grain flour
WO2012009644A3 (en) Methods to identify synthetic and natural rna elements that enhance protein translation
MX348071B (es) Variantes de fc.
EP4282881A3 (en) Antibodies against csf-1r
WO2008121324A3 (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
WO2021007504A3 (en) Methods and compositions comprising reduced level of host cell proteins
BR112013020889A2 (pt) composições nutricionais solúveis em água compreendendo beta-glucana de cereal e amido resistente
WO2012007916A3 (en) Plants having enhanced yield-related traits and method for making the same
WO2013025928A3 (en) Methods for extracting keratin proteins
WO2011054929A3 (fr) Procede de production de triptolide
Wang et al. Production of bioactive peptides from soybean meal by solid state fermentation with lactic acid bacteria and protease
WO2011000933A3 (fr) Variants ameliores d'une phytase
NZ603033A (en) Methods for g-csf production in a pseudomonas host cell
WO2011159092A3 (ko) 신규 토양 미생물과 상기 토양 미생물로부터 분리된 신규한 산화환원효소, 상기 산화환원 효소를 암호화하는 유전자 및 이들을 이용한 비당체의 생산방법
MD20130099A2 (ro) Expresia recombinantă a interferonului solubil
MX2013000842A (es) Produccion a base de plantas de las proteínas heterólogas.
WO2011011562A3 (en) Maintaining a direct connection between an initiator and a drive
Boekhout et al. Bullera Derx (1930)
WO2013043033A3 (es) Método de extracción, comprobacíon de extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferecia potencializado, específicamente diseñado para su uso como adyuvante potencializador de vacunas virales

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed
S35A Application for proceedings under section 35 (restoration of lapsed patents)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2017 BY GRIFFITH HACK

Effective date: 20160229

S35R Proceedings under section 35 (restoration of lapsed patents): patent restored
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2018 BY CPA GLOBAL

Effective date: 20170120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2019 BY CPA GLOBAL

Effective date: 20180118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 MAR 2020 BY CPA GLOBAL

Effective date: 20190117

LAPS Patent lapsed